Friday 9^th October 2015

13:30      Welcome and introduction (D. Betticher, Fribourg)

Pathology (D. Betticher)

13:35      Lung pathology at the era of 2015 WHO classification and ongoing segmentation based on oncogenic events (I. Letovanec, Lausanne)

Standards in NSCLC treatments (S. Peters)

14:05      Multidisciplinary management of locally advanced NSCLC (M. Pless, Winterthur)

14:35      No target in advanced disease, which therapies? (D. Betticher, Fribourg)

15:05      Known targets, which therapies in 1^st, 2^nd and 3^rd line? (O. Gautschi, Luzern)

15:35      Coffee break

Immunotherapy in NSCLC (R. Stahel)

16:00      Checkpoint inhibitors. How does it work and available data? (S. Peters, Lausanne)

16:30      Combination strategies (D. Carbone, Columbus)

17:00      How has/will immunotherapy enter the NSCLC treatment portfolio including ongoing clinical and translational (A. Zippelius, Basel)

Mesothelioma (M. Pless)

17:30      Which radiotherapy? (O. Riesterer, Zürich)

18:00      Which systemic treatment? (R. Stahel, Zürich)

18:30      Adjourn

Saturday 10^th October 2015

SCLC (D. Betticher)

08:00      New chemotherapy options? (N. Mach, Genève)

08:30      PCI or no PCI, thoracic RT or not, when, how, to whom? (S. Senan, Amsterdam)

09:00      Resection, an option? (J. Perentes, Lausanne)

09:30      Coffee break

Interactive session and case presentations (R. Stahel)

10:00      Daily practice in the treatment of NSCLC, examples (A. Curioni, Zürich/S. Zimmermann, Fribourg)

Challenges and new developments (S. Peters)

11:00      Have new radiotherapy technologies improved outcomes in lung cancer (S. Senan, Amsterdam)

11:20      Combination radiotherapy and targeted therapies (O. Riesterer, Zürich)

11:40      Combination TKI and immunotherapy (D. Carbone, Columbus)

12.00      Wrap-up and conclusions (S. Peters, Lausanne)